Financial Personal
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
The agreement builds on Organon’s global product portfolio for conditions that impact women disproportionately. Women are three times more likely to experience migraine than men.i JERSEY CITY, N.J. — Organon (NYSE: OGN), a global healthcare com
JERSEY CITY, N.J. -- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicine Emgality® (galcanezumab) in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. This expanded partnership builds on Organon’s role as sole distributor and promoter of Emgality in Europe since February 2024. Read More
